Financial reports
10-Q
2023 Q2
Quarterly report
8 Aug 23
10-Q
2023 Q1
Quarterly report
11 May 23
ARS
2022 FY
Annual report to shareholders
26 Apr 23
10-K
2022 FY
Annual report
15 Mar 23
10-Q
2022 Q3
Quarterly report
9 Nov 22
10-Q
2022 Q2
Quarterly report
11 Aug 22
10-Q
2022 Q1
Quarterly report
12 May 22
10-K
2021 FY
Annual report
28 Mar 22
10-Q
2021 Q3
Quarterly report
12 Nov 21
Current reports
8-K
Termination of a Material Definitive Agreement
9 Aug 23
8-K
Lilly to Acquire DICE Therapeutics to Advance Innovation in Immunology
20 Jun 23
8-K
Amendments to Articles of Incorporation or Bylaws
7 Jun 23
8-K
DICE Therapeutics Reports First Quarter 2023 Financial Results and Recent Highlights
11 May 23
8-K
DICE Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights
15 Mar 23
8-K
Departure of Directors or Certain Officers
10 Feb 23
8-K
Amendments to Articles of Incorporation or Bylaws
17 Nov 22
8-K
DICE Therapeutics Reports Third Quarter 2022 Financial Results and Recent Highlights
9 Nov 22
8-K
DICE Announces Pricing of Upsized Public Offering of Common Stock
13 Oct 22
8-K
DICE Therapeutics Announces Positive Topline Data from Phase 1 Clinical Trial of Lead Oral IL-17
11 Oct 22
Registration and prospectus
15-12G
Securities registration termination
21 Aug 23
S-8 POS
Registration of securities for employees (post-effective amendment)
9 Aug 23
S-8 POS
Registration of securities for employees (post-effective amendment)
9 Aug 23
S-8 POS
Registration of securities for employees (post-effective amendment)
9 Aug 23
POSASR
Automatic shelf registration (post-effective amendment)
9 Aug 23
POS AM
Prospectus update (post-effective amendment)
9 Aug 23
SC 14D9/A
Tender offer solicitation (amended)
9 Aug 23
SC TO-T/A
Third party tender offer statement (amended)
9 Aug 23
25-NSE
Exchange delisting
9 Aug 23
SC 14D9/A
Tender offer solicitation (amended)
25 Jul 23
Other
EFFECT
Notice of effectiveness
11 Aug 23
EFFECT
Notice of effectiveness
11 Oct 22
CORRESP
Correspondence with SEC
5 Oct 22
UPLOAD
Letter from SEC
4 Oct 22
EFFECT
Notice of effectiveness
15 Sep 21
SEC STAFF
SEC staff action: Order
15 Sep 21
CERT
Certification of approval for exchange listing
10 Sep 21
CORRESP
Correspondence with SEC
10 Sep 21
CORRESP
Correspondence with SEC
10 Sep 21
CORRESP
Correspondence with SEC
27 Aug 21